In our latest Healthcare & Life Sciences podcast, Leolie Telford-Cooke talks to Dr Chris Coughlin CEO of Avacta (N/R). Chris walks us through some of the clinical data so far produced from a Phase I trial of the company’s lead asset, AVA6000, a novel peptide drug conjugate of the classical chemotherapy agent doxorubicin.
Listen to the podcast below.
